Benefits Medical Cannabis Studies

A

• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)

B

• batten-disease (6)

• benefits (9)

• breast-cancer (7)

C

• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)

D

• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)

E

• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)

F

• fibromyalgia (2)

• fibrosis (1)

G

• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)

H

• health-care (1)

• hiv (7)

• huntingtons-disease (1)

I

• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)

K

• krabbe-disease (4)

L

• liver (2)

• lung-cancer (2)

• lupus (1)

M

• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)

N

• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)

P

• pain (29)

• pancreatitis (1)

• prostate-cancer (2)

S

• schizophrenia (2)

• skin (1)

• sports (3)

T

• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • A prospective observational study of problematic oral cannabinoid use. (2017)

    The present study focused on two objectives. The first objective of this study was to examine the incidence of problematic use of prescription cannabinoids (PPCBU) over a period of 12 months among patients who started treatment with cannabinoids. The second objective was to examine the factors associated with PPCBU. View study

  • Altered striatal reward processing in abstinent dependent cannabis users: Social context matters. (2019)

    The public perception of cannabis as relatively harmless, together with the declared medical benefits, has led to progress towards its legalization. The present study aimed to investigate whether cannabis dependence is associated with lasting alterations in behavioral and neural responses to social reward in 23 abstinent cannabis-dependent men and 24 matched non-using controls. View study

  • Cannabinoids stimulate the TRP-channel dependent release of both serotonin and dopamine to modulate behavior in C. elegans. (2019)

    The purpose of this study was to highlight the advantages of identifying and evaluating CB1 / CB2 dependent and independent cannabinoid signaling pathways in a genetically treatable mammalian predictive model, in which cannabinoid signaling at the molecular / neuronal level can directly correlate with changes in behavior View study

  • Cannabis for pediatric epilepsy: protocol for a living systematic review. (2018)

    Pediatric epilepsy, including treatment-resistant forms, has a greater effect on the quality of life, morbidity, and mortality of affected children. The present systematic revision will have the purpose of seeking, synthesizing, evaluating the published literature in order to provide usable and relevant information to parents, clinicians, and policy makers View study

  • Cannabis Use Disorder. (2019)

    Cannabis is considered by the Food and Drug Administration, along with heroin and peyote, as a drug program. It has no accepted medical purpose and has a high potential for abuse. This article aimed to focus on the abuse of cannabis and related components, states of intoxication and abstinence, and cannabis use disorder. View study

  • Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. (2019)

    Drug-resistant epilepsy has a negative impact on quality of life and is associated with increased morbidity and mortality and high costs for the health system. The purpose of this systematic review was to look for cost-effectiveness analyzes that include the treatment of pediatric drug-resistant epilepsy with cannabis-based products to inform public health payers about making decisions about the reimbursement of these products. View study

  • Medical Cannabis. (2018)

    Patients increasingly ask physicians to share information about them or to certify them for medical cannabis. The objective of this review was to provide a general description of the legal status, pharmacology, benefits, risks and responsibility of abuse. of medicinal cannabis together with a general framework to advise patients. View study

  • Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients. (2018)

    The objective of this research was to review the benefits and risks of cannabis use, with emphasis on the processes of otorhinolaryngological diseases, as well as to define and review the endocannabinoid signaling system (ESS) and review the state and federal regulations for the use of cannabis. Research on cannabis modulators and ESS. View study

  • Vaporization of Marijuana Among Recreational Users: A Qualitative Study. (2019)

    The objective of the present qualitative study was to examine the cognitions related to vaping among recreational users of marijuana. It was concluded that Quantitative research is needed to examine the extent to which cognitions about marijuana vaporization contribute to current use patterns and problematic behaviors. View study